Regeneron Pharmaceuticals (NASDAQ:REGN) Given New $1,075.00 Price Target at Barclays

Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) had its price objective hoisted by Barclays from $917.00 to $1,075.00 in a research report issued on Tuesday, Benzinga reports. The brokerage presently has an “overweight” rating on the biopharmaceutical company’s stock. Barclays‘s price target would indicate a potential upside of 12.24% from the stock’s current price.

Several other brokerages also recently weighed in on REGN. The Goldman Sachs Group boosted their target price on Regeneron Pharmaceuticals from $965.00 to $972.00 and gave the stock a “buy” rating in a research note on Friday, July 31st. JPMorgan Chase & Co. increased their price objective on shares of Regeneron Pharmaceuticals from $950.00 to $1,050.00 and gave the company an “overweight” rating in a research report on Friday, October 30th. Wells Fargo & Company upped their price target on shares of Regeneron Pharmaceuticals from $750.00 to $925.00 and gave the company an “equal weight” rating in a research note on Monday, November 2nd. Raymond James Financial boosted their price target on Regeneron Pharmaceuticals from $902.00 to $911.00 and gave the company an “outperform” rating in a research note on Friday, July 31st. Finally, Guggenheim upped their price target on shares of Regeneron Pharmaceuticals from $1,030.00 to $1,100.00 and gave the company a “buy” rating in a report on Monday, November 2nd. One research analyst has rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and nine have assigned a Hold rating to the stock. Based on data from MarketBeat, Regeneron Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $904.41.

Check Out Our Latest Research Report on Regeneron Pharmaceuticals

Regeneron Pharmaceuticals Trading Up 0.6%

Shares of REGN stock traded up $5.40 on Tuesday, reaching $957.80. 303,229 shares of the company’s stock were exchanged, compared to its average volume of 835,621. The company’s fifty day simple moving average is $818.67 and its 200 day simple moving average is $748.36. The stock has a market capitalization of $99.08 billion, a PE ratio of 21.16, a P/E/G ratio of 1.26 and a beta of 0.10. The company has a current ratio of 3.35, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06. Regeneron Pharmaceuticals has a 52 week low of $591.52 and a 52 week high of $991.73.

Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) last issued its earnings results on Friday, October 30th. The biopharmaceutical company reported $20.07 earnings per share for the quarter, beating analysts’ consensus estimates of $16.51 by $3.56. Regeneron Pharmaceuticals had a return on equity of 16.01% and a net margin of 28.51%. The business had revenue of $5.12 billion during the quarter, compared to analyst estimates of $4.58 billion. During the same period in the previous year, the company posted $11.83 EPS. Regeneron Pharmaceuticals’s revenue was up 36.3% on a year-over-year basis. As a group, analysts forecast that Regeneron Pharmaceuticals will post 58.26 EPS for the current year.

Insider Transactions at Regeneron Pharmaceuticals

In other news, Director Kathryn Guarini sold 400 shares of Regeneron Pharmaceuticals stock in a transaction on Friday, October 30th. The stock was sold at an average price of $900.00, for a total transaction of $360,000.00. Following the completion of the transaction, the director owned 603 shares of the company’s stock, valued at $542,700. The trade was a 39.88% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Joseph J. Larosa sold 4,466 shares of Regeneron Pharmaceuticals stock in a transaction dated Monday, November 2nd. The stock was sold at an average price of $965.49, for a total value of $4,311,878.34. Following the sale, the executive vice president owned 38,906 shares of the company’s stock, valued at approximately $37,563,353.94. This represents a 10.30% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 27,028 shares of company stock worth $25,025,950. Insiders own 6.97% of the company’s stock.

Hedge Funds Weigh In On Regeneron Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in REGN. BlackRock Inc. acquired a new position in Regeneron Pharmaceuticals in the second quarter valued at approximately $5,682,636,000. State Street Corp grew its stake in shares of Regeneron Pharmaceuticals by 1.0% in the 3rd quarter. State Street Corp now owns 4,881,362 shares of the biopharmaceutical company’s stock worth $3,701,390,000 after purchasing an additional 46,674 shares during the last quarter. Bank of America Corp DE grew its holdings in shares of Regeneron Pharmaceuticals by 2.8% in the 1st quarter. Bank of America Corp DE now owns 1,189,584 shares of the biopharmaceutical company’s stock worth $919,120,000 after acquiring an additional 32,158 shares during the last quarter. Amundi lifted its stake in Regeneron Pharmaceuticals by 27.5% during the first quarter. Amundi now owns 1,009,798 shares of the biopharmaceutical company’s stock valued at $780,210,000 after buying an additional 217,892 shares in the last quarter. Finally, First Trust Advisors LP raised its stake in Regeneron Pharmaceuticals by 51.1% during the 3rd quarter. First Trust Advisors LP now owns 826,770 shares of the biopharmaceutical company’s stock valued at $626,915,000 after purchasing an additional 279,638 shares during the period. 83.31% of the stock is owned by hedge funds and other institutional investors.

About Regeneron Pharmaceuticals

(Get Free Report)

Regeneron Pharmaceuticals, Inc. is a biotechnology company that discovers, develops, manufactures and commercializes medicines for serious diseases. Its research and product portfolio spans areas including eye disease, allergic and inflammatory conditions, cancer, cardiovascular and metabolic disorders, infectious diseases and rare conditions. The company’s medicines include EYLEA for certain eye diseases, Dupixent for inflammatory conditions and Libtayo for cancer. Regeneron also develops and markets treatments with pharmaceutical partners, including Sanofi, and its products reach patients in the United States and international markets through its own operations and collaborations.

Further Reading

Analyst Recommendations for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.